OKYO Pharma (OKYO) Receivables - Other (2021 - 2025)
OKYO Pharma (OKYO) reported Receivables - Other of $422281.0 for Q3 2025, up 18.51% year-over-year from $356329.0 in Q3 2024, and down 77.44% quarter-over-quarter from $1.9 million in Q1 2025.
OKYO Pharma (OKYO) Receivables - Other (2021 - 2025) Analysis & Trends
OKYO Pharma (OKYO) has 5 years of Receivables - Other data on file, last reported at $422281.0 in Q3 2025.
- Receivables - Other for Q3 2025 came in at $422281.0, up 18.51% year-over-year; the trailing twelve-month figure through Sep 2025 was $422281.0 (up 18.51% YoY), and the FY2025 annual result was $4500.0, down 19.43% from the prior year.
- Receivables - Other retreated to $422281.0 in Q3 2025 per OKYO's latest filing, from $1.9 million in the prior quarter.
- Over five years, Receivables - Other peaked at $1.9 million in Q1 2025 and troughed at $5585.0 in Q1 2024.
- A 5-year average of $519149.1 and a median of $348588.5 in 2023 frame the typical range for Receivables - Other.
- The sharpest annual moves came in 2024 and 2025: Receivables - Other tumbled 98.36% in 2024, then jumped 33419.37% in 2025.
- A 5-year view of Receivables - Other shows it stood at $43371.0 in 2021, then jumped by 1774.42% to $812956.0 in 2022, then sank by 63.13% to $299766.0 in 2023, then grew by 18.87% to $356329.0 in 2024, then increased by 18.51% to $422281.0 in 2025.
- Business Quant data shows OKYO's Receivables - Other at $422281.0 in Q3 2025, $1.9 million in Q1 2025, and $356329.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - |
| 10 | OKYO Pharma | 244.98 Mn | 240.76 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 422,281.00 |
| Sep 30, 2025 | 422,281.00 |
| Mar 31, 2025 | 1.87 Mn |
| Mar 31, 2025 | 1.87 Mn |
| Sep 30, 2024 | 356,329.00 |
| Sep 30, 2024 | 356,329.00 |
| Mar 31, 2024 | 5,585.00 |
| Mar 31, 2024 | 5,585.00 |
| Sep 30, 2023 | 299,766.00 |
| Sep 30, 2023 | 299,766.00 |
| Mar 31, 2023 | 340,848.00 |
| Mar 31, 2023 | 340,848.00 |
| Mar 31, 2022 | 812,956.00 |
| Mar 31, 2022 | 812,956.00 |
| Mar 31, 2021 | 43,371.00 |
| Mar 31, 2021 | 43,371.00 |